TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+14.41%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.85B
AUM Growth
+$2.85B
(+6.6%)
Cap. Flow
-$35.8M
Cap. Flow
% of AUM
-1.26%
Top 10 Holdings %
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
41
Reduced
45
Closed
16
Top Buys
| 1 |
Thermo Fisher Scientific
TMO
|
$45.7M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$36.7M |
| 3 |
Danaher
DHR
|
$33.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$22.1M |
| 5 |
DexCom
DXCM
|
$20.7M |
Top Sells
| 1 |
Amgen
AMGN
|
$44.1M |
| 2 |
Merck
MRK
|
$40.6M |
| 3 |
Pfizer
PFE
|
$36.5M |
| 4 |
AbbVie
ABBV
|
$27.3M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$22.7M |
Sector Composition
| 1 | Healthcare | 95.34% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ascendis Pharma
ASND
$11.8B
| $16.1M | 0.56% | 96,246 -29,500 | -23% | -$4.92M |
|
52
Sutro Biopharma
STRO
$72.7M
| $15.3M | 0.54% | 702,523 +61,255 | +10% | +$1.33M |
|
53
NovoCure
NVCR
$1.38B
| $15.2M | 0.53% | 87,918 -28,927 | -25% | -$5.01M |
|
54
Guardant Health
GH
$8.41B
| $15.2M | 0.53% | 117,852 | – | – |
|
55
Fate Therapeutics
FATE
$120M
| $15.1M | 0.53% | 166,317 -51,145 | -24% | -$4.65M |
|
56
CVS Health
CVS
$92.8B
| $15M | 0.53% | 219,995 -168,268 | -43% | -$11.5M |
|
|
TPTX
57
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $14.5M | 0.51% | 119,324 +113,647 | +2,002% | +$13.8M |
|
|
BPMC
58
DELISTED
Blueprint Medicines
BPMC
| $13.8M | 0.48% | 122,699 -47,319 | -28% | -$5.31M |
|
59
Novartis
NVS
$245B
| $13.6M | 0.48% | 144,525 -7,000 | -5% | -$661K |
|
60
IQVIA
IQV
$32.4B
| $13.6M | 0.48% | 76,066 -6,200 | -8% | -$1.11M |
|
61
Ultragenyx Pharmaceutical
RARE
$2.89B
| $13.5M | 0.47% | 97,480 | – | – |
|
|
SYNH
62
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $13.3M | 0.47% | 195,136 +87,135 | +81% | +$5.94M |
|
|
SAGE
63
DELISTED
Sage Therapeutics
SAGE
| $13.2M | 0.46% | 152,040 +55,829 | +58% | +$4.83M |
|
64
Labcorp
LH
$23.1B
| $13.2M | 0.46% | 64,603 -5,400 | -8% | -$1.1M |
|
65
Welltower
WELL
$113B
| $13.1M | 0.46% | 203,083 | – | – |
|
66
Quest Diagnostics
DGX
$20.3B
| $13.1M | 0.46% | 109,659 | – | – |
|
67
Iovance Biotherapeutics
IOVA
$807M
| $12.6M | 0.44% | 271,073 | – | – |
|
68
Apellis Pharmaceuticals
APLS
$3.48B
| $12.4M | 0.43% | 216,017 | – | – |
|
|
TRIL
69
DELISTED
Trillium Therapeutics Inc.
TRIL
| $12M | 0.42% | 817,784 +369,735 | +83% | +$5.44M |
|
70
Elevance Health
ELV
$71.8B
| $11.9M | 0.42% | 37,133 | – | – |
|
71
CRISPR Therapeutics
CRSP
$4.71B
| $11.7M | 0.41% | 76,222 | – | – |
|
|
ITCI
72
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.6M | 0.41% | 366,176 +271,938 | +289% | +$8.65M |
|
73
Teladoc Health
TDOC
$1.37B
| $11.3M | 0.4% | +56,520 | New | +$11.3M |
|
74
Mettler-Toledo International
MTD
$26.8B
| $11.2M | 0.39% | 9,800 | – | – |
|
75
Jazz Pharmaceuticals
JAZZ
$7.75B
| $11.1M | 0.39% | 67,456 | – | – |
|